BioPharma Clinical Trials
XtalPi And ReviR Dose First Participant In Phase One Trial Of RTX 117 For Rare Neurological Disorders
RTX-117 is an investigational small molecule designed to modulate the Integrated Stress Response (ISR) pathway, with the goal of restoring protein transl...
March 04, 2026 | News
Ono Pharmaceutical And Congruence Expand Research Alliance Into Neurology And Immunology
Expanded collaboration continues to leverage Congruence's proprietary computational drug discovery engine, Revenir™ to deliver Development Candi...
March 04, 2026 | News
Hua Medicine Secures First Glucokinase Activator Approval Outside Mainland China In Hong Kong
First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to Type 2 diabetes (T2D) ma...
March 04, 2026 | News
Innovent Secures China Approval For Jaypirca In Previously Treated CLL And SLL
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
March 03, 2026 | News
Lynk Pharmaceuticals Reports Positive Phase III Results For Zemprocitinib In Atopic Dermatitis
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammat...
March 03, 2026 | News
Genentech Reports Phase III Success For Fenebrutinib With 51 Percent Relapse Reduction In Multiple Sclerosis
- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relap...
March 03, 2026 | News
Takeda And Protagonist Secure FDA Priority Review For Rusfertide In Polycythemia Vera
Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythem...
March 03, 2026 | News
Pfizer And Astellas Report Strong Phase III EV 304 Results For PADCEV Plus Pembrolizumab In MIBC
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with ove...
March 02, 2026 | News
SystImmune And Bristol Myers Squibb Report Dual PFS And OS Success For Iza Bren In Phase III TNBC Trial
Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (“PFS”) and overall survival (“OS”...
March 02, 2026 | News
Optellum Secures TGA Approval In Australia For AI Powered Virtual Nodule Clinic
Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration ...
March 02, 2026 | News
Gilead Reports Positive Phase 3 Data For Investigational Bictegravir And Lenacapavir Single Tablet Regimen
– Novel Investigational Combination Pairs Bictegravir, a Global Guideline-Recommended Integrase Strand Transfer Inhibitor with a High Barrier ...
February 27, 2026 | News
Suvoda Introduces Split Budget Capability To Streamline Global Clinical Trial Site Agreements
Suvoda, a clinical trial technology company announced new split budget functionality within its Budgeting & Benchmarking solution, expanding how sponso...
February 27, 2026 | News
Japan Approves Alpha DaRT To Expand Treatment Options In Head And Neck Cancer
Offering a New Option for Head and Neck Cancer Treatment HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor tr...
February 27, 2026 | News
AtomVie Supplies First Patient Dose In Radiopharm Theranostics Phase 1 2a Study Of 177Lu BetaBart
AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first pat...
February 26, 2026 | News
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
